Ariad Pharmaceutical Downgraded by Oppenheimer (ARIA)

Oppenheimer lowered shares of Ariad Pharmaceutical (NASDAQ: ARIA) from an outperform rating to a perform rating in a report released on Tuesday. Oppenheimer currently has $23.00 target price on the stock, up from their previous target price of $20.00.

Share